I believe a parnter announcement is not if, but when, and sooner than later with the Fast Track status. Initially milestone is $5 mil. cash to AmphiPhi.with another $15 mil throughout the process to approval then significant royalties.
Pretty simple math on the stock price multipler with a Phase 3 MYDICAR, and believe me that is well north of $1.
According to data on FDA website, Fast Track has generated the following workload from March 1998 to September 2011: Submitted 248 applications
Reviewed within 60 days:
Granted - 152
Denied - 87
Currently pending - 2
The Fast Track designation is not a guarantee of a partner. In fact, it is still very challenging since it would be the first and only ever FDA-approved gene therapy.
But, there are still other projects going for it, right?
Nothing is guaranteed in the markets. Do the math. About 10 fast track approvals are granted a year by the FDA. MYDICAR has passed Phase 2 safety with significant efficacy. Highly unlikely a blockbuster $$ gene therapy that is Phase 3 ready won't find a large Bio/Pharma partner soon.
I hope that's the case because if KP invests more into Celladon, already have a private stake, they are doing so for one drug candidate and that's the MYDICAR trial.
Joseph Lacob is a long time General Partner at KPCB & was a former advisory board member at Celladon.
Also,Venrock Associates another premier venture capital firm has invested into Celladon & will help them identify a Phase 3 partner.
To me it's not a question of if but when with MYDICAR Phase 3 and that annoucement will catipult AmpliPhi's value based on the current market cap. of $2.4 mil of so.
this is all wishfull thinking which in general is a good thing!!!
until this stock will not upgrade to a better listing and will start show some transperecy to the share holders, it will not cross the 1$ if any.
it will not atract enogh investors that will take to this highets....
i'm long on this one and hoping to see that move soon...